SURMOUNT-5 Head-to-Head Superiority
Tirzepatide superior to semaglutide for weight loss in head-to-head Phase 3 trial in patients with obesity without T2D. Cost-effectiveness analysis: $41,688 per-patient savings and 0.506 QALYs gained.
[1]A synthetic 39-amino-acid dual agonist at the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, developed by Eli Lilly. FDA approved as Mounjaro (2022) for type 2 diabetes, Zepbound (2023) for chronic weight management, and (2024) for moderate to severe obstructive sleep apnea associated with obesity. The dual incretin mechanism produces superior weight loss to semaglutide in head-to-head trials.
At a glance
- Type
- Synthetic 39-amino-acid dual GLP-1 and GIP receptor agonist
- Developer
- Eli Lilly
- Formulations
- Mounjaro (type 2 diabetes, 2022), Zepbound (chronic weight management, 2023), moderate to severe OSA with obesity (2024)
- Regulatory
- FDA approved
- Dosing
- Once weekly, 2.5 mg start, escalating in 4 week steps to 15 mg
- Boxed warning
- MTC / MEN2 personal or family history
What the research supports
Tirzepatide's evidence base spans the SURMOUNT and SURPASS programs, head-to-head superiority over semaglutide, OSA approval, and emerging T1DM adjunct applications.
T1DM Adjunct Meta-Analysis
In adults with T1DM and obesity: HbA1c reduction 0.61%, body weight reduction 9.9 kg, total daily insulin reduction 23.73 IU/day at 6 months.
[2]Incretin BP and Mortality Meta-Analysis
Dual agonists produce SBP reduction 5.1 mmHg, DBP reduction 1.8 mmHg, and substantial all-cause mortality reduction across class.
[3]SURMOUNT-OSA
Significant reduction in apnea-hypopnea index in patients with obesity and OSA, leading to 2024 FDA approval for the OSA indication.
[4]Summary of key findings
Superior Weight Loss in Head-to-Head
SURMOUNT-5 confirmed tirzepatide superiority over semaglutide; 20+ percent mean weight loss at maximum dose.
Dual Mechanism Advantage
GLP-1 plus GIP activation addresses both major incretin pathways for greater weight loss and glycemic improvement.
OSA Indication
2024 FDA approval for moderate-to-severe OSA in adults with obesity; substantial AHI reduction often follows weight loss.
CV Outcomes Data Thinner Than Semaglutide
For established cardiovascular disease, semaglutide still has the stronger outcomes data (SELECT trial).
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- Zepbound and Mounjaro FDA Titration
- Weeks 1 to 4: start 2.5 mg once weekly. Weeks 5 to 8: escalate to 5 mg. Weeks 9 to 12: escalate to 7.5 mg. Weeks 13 to 16: escalate to 10 mg. Weeks 17 to 20: escalate to 12.5 mg. Then 15 mg. Four weeks per step.
- Oral Contraceptive Interaction
- Use backup contraception during the first 4 weeks after each dose escalation due to delayed gastric emptying.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| Tirzepatide 20 mg / 2 mL | 2.5 to 15 mg | 25 to 150 units | 1x per week | 0.1 mg per unit. |
| Tirzepatide 30 mg / 3 mL | 2.5 to 15 mg | 25 to 150 units | 1x per week | 0.1 mg per unit. |
| Tirzepatide 40 mg / 3 mL | 2.5 to 15 mg | about 19 to 113 units | 1x per week | About 0.133 mg per unit (13.3 mg/mL). |
| Tirzepatide 50 mg / 3 mL | 2.5 to 15 mg | 15 to 90 units | 1x per week | About 0.167 mg per unit (16.7 mg/mL). |
| Tirzepatide 60 mg / 3 mL | 2.5 to 15 mg | 12.5 to 75 units | 1x per week | 0.2 mg per unit. |
| Tirzepatide 75 mg / 3 mL | 2.5 to 15 mg | 10 to 60 units | 1x per week | 0.25 mg per unit. |
| Tirzepatide 100 mg / 4 mL | 2.5 to 15 mg | 10 to 60 units | 1x per week | 0.25 mg per unit; 25 mg/mL reconstituted. |
| FDA titration | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg | 1x per week | 4 weeks per step. |
For most obesity patients without T2D, tirzepatide is preferred over semaglutide. For established CVD, semaglutide has more outcomes data.
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
Tirzepatide is the preferred first-line GLP-1 class option for most obesity patients without established cardiovascular disease, with SURMOUNT-5 superiority over semaglutide and cost-effectiveness confirmed. The dual GLP-1 plus GIP mechanism produces 20+ percent mean weight loss at maximum dose, approaching retatrutide territory without glucagon receptor effects. For established CVD, semaglutide retains stronger outcomes data.
The 2024 OSA indication is clinically meaningful: patients with obesity and OSA often see substantial AHI reduction, sometimes eliminating CPAP requirement. Oral contraceptive interaction during titration is real; use backup contraception during titration weeks. Slow titration matters for tolerability.
Superior Weight Loss
Mean 20+ percent reduction at maximum dose; SURMOUNT-5 superiority over semaglutide confirmed.
Dual Incretin Mechanism
GLP-1 plus GIP activation for greater weight loss and glycemic improvement across both major incretin pathways.
OSA Indication
2024 FDA approval for moderate-to-severe obstructive sleep apnea with obesity; substantial AHI reduction observed.
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Johansson et al., 2026 SURMOUNT-5 Cost-Effectiveness: Tirzepatide vs Semaglutide Head-to-Head
- 2Soliman et al., 2026 T1DM Adjunct Meta-Analysis: Tirzepatide as Adjunct Therapy in Type 1 Diabetes
- 3Basile et al., 2026 Incretin BP and Mortality Meta-Analysis: Incretin-Based Therapies on Blood Pressure
- 4Malhotra et al., 2024 SURMOUNT-OSA: Tirzepatide for OSA with Obesity
Regulatory status, cautions and contraindications
Boxed Warning Contraindication
MTC / MEN2 personal or family history is a boxed-warning contraindication.
Pregnancy
Pregnancy is contraindicated; discontinue at least 2 months before planned conception.
Oral Contraceptive Interaction
Oral contraceptive interaction during titration weeks: use backup contraception.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.